This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Burke, J. Search for Related Content Social Bookmarking                         What's this?

Review: Combination treatment with insulin and oral agents in type 2 diabetes mellitus

Thames House, Barnet General Hospital, Wellhouse Lane, Barnet Hertfordshire, EN5 3DJ, UK, john.burke{at}barnet-chase-tr.nhs.uk

The need to improve glycaemic control in type 2 diabetes has been reinforced by the United Kingdom Prospective Diabetes Study (UKPDS). Due to progressive deterioration of beta-cell function after diagnosis, oral hypoglycaemic agents often fail to maintain adequate glycaemic control after only a few years of treatment. This paper considers the treatment options available at this stage and reassures diabetologists that the combined use of insulin plus metformin with or without an added sulphonylurea is logical, is as effective as insulin alone, and provides superior weight regulation in many patients. A. combination of metformin with glargine insulin seems particularly effective and well tolerated. The long-term advantages of such treatments in terms of clinical outcomes have yet to be demonstrated in clinical trials.

Key Words: insulin • oral antidiabetic agent • type 2 diabetes • metformin • sulphonylurea • thiazolidinedione • combination therapy.

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 2, 71-76 (2004)
DOI: 10.1177/14746514040040020201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?